Search - Université de Rennes Access content directly

Filter your results

23 Results
authFullName_s : Xavier Roblin

Determinants of IBD-related disability: a cross-sectional survey from the GETAID.

Jenny Tannoury , Maria Nachury , Carole Martins , Melanie Serrero , Jerome Filippi et al.
Alimentary Pharmacology & Therapeutics (Suppl), 2021, 53 (10), pp.1098-1107. ⟨10.1111/apt.16353⟩
Journal articles hal-03216615v1
Image document

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

Cassandra Rayer , Maria Nachury , Arnaud Bourreille , Xavier Roblin , Laurent Peyrin-Biroulet et al.
BMC Gastroenterology, 2023, 23 (1), pp.31. ⟨10.1186/s12876-022-02636-9⟩
Journal articles hal-03980994v1
Image document

Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group

Maria Nachury , Yoram Bouhnik , Mélanie Serrero , Jerome Filippi , Xavier Roblin et al.
Digestive and Liver Disease, 2021, 53 (4), pp.434-441. ⟨10.1016/j.dld.2020.10.020⟩
Journal articles hal-03038260v1

Obesity in adult patients with inflammatory bowel disease: Clinical features and impact on disability. A cross-sectional survey from the GETAID

Rose Al Bacha , Yoram Bouhnik , Melanie Serrero , Jerome Filippi , Xavier Roblin et al.
Digestive and Liver Disease, 2023, ⟨10.1016/j.dld.2023.05.008⟩
Journal articles hal-04113898v1
Image document

Should we set-up routine screening for primary sclerosing cholangitis in all IBD patients?

Guillaume Bouguen , Miles Peter Sparrow , Xavier Roblin
Digestive and Liver Disease, 2018, 50 (11), pp.1176-1177. ⟨10.1016/j.dld.2018.07.043⟩
Journal articles hal-01903476v1

Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn's Disease.

Guillaume Bouguen , David Laharie , Stéphane Nancey , Xavier Hebuterne , Bernard Flourie et al.
Inflammatory Bowel Diseases, 2015, 21 (5), pp.1047-1053. ⟨10.1097/MIB.0000000000000359⟩
Journal articles hal-01138534v1
Image document

Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study

Mathurin Fumery , Laurent Peyrin-Biroulet , Stéphane Nancey , Romain Altwegg , Cyrielle Gilletta et al.
Journal of Crohn's and Colitis, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩
Journal articles hal-02959922v1
Image document

Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis

Loriane Lair-Mehiri , Carmen Stefanescu , Thibaut Vaysse , David Laharie , Xavier Roblin et al.
Digestive and Liver Disease, 2020, 52 (3), pp.268-273. ⟨10.1016/j.dld.2019.10.003⟩
Journal articles hal-03287300v1
Image document

INFLIXIMAB FOR REFRACTORY ULCERATIVE PROCTITIS

Guillaume Bouguen , Xavier Roblin , Arnaud Bourreille , Laura Feier , Jérôme Filippi et al.
Alimentary Pharmacology and Therapeutics, 2010, 31 (11), pp.1178. ⟨10.1111/j.1365-2036.2010.04293.x⟩
Journal articles hal-00552545v1

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

Mathurin Fumery , Jerome Filippi , Vered Abitbol , Amelie Biron , David Laharie et al.
Alimentary Pharmacology and Therapeuthics, 2021, 54 (7), pp.944-951. ⟨10.1111/apt.16544⟩
Journal articles hal-03336375v1
Image document

Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study

Laura Sirmai , Anne-Laure Pelletier , Nathalie Gault , Camille Zallot , Guillaume Bouguen et al.
World Journal of Gastroenterology, 2022, 28 (9), pp.961-972. ⟨10.3748/wjg.v28.i9.961⟩
Journal articles hal-03625177v1
Image document

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

Aurelien Amiot , Jerome Filippi , Vered Abitbol , Guillaume Cadiot , David Laharie et al.
Alimentary Pharmacology and Therapeutics, 2020, 51 (11), pp.1039-1046. ⟨10.1111/apt.15717⟩
Journal articles hal-02798010v1
Image document

Prevalence and determinants of fatigue in patients with IBD: a cross-sectional survey from the GETAID.

Aurelien Amiot , Sayma Chaibi , Yoram Bouhnik , Melanie Serrero , Jerome Filippi et al.
Journal of Crohn's & Colitis, 2023, pp.jjad060. ⟨10.1093/ecco-jcc/jjad060⟩
Journal articles hal-04052487v1

Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study

Marianne Hupe , Pauline Riviere , Stephane Nancey , Xavier Roblin , Romain Altwegg et al.
Alimentary Pharmacology and Therapeutics, 2020, 51 (9), pp.852-860. ⟨10.1111/apt.15680⟩
Journal articles hal-02562228v1
Image document

Detection of Dysplasia or Cancer in 3.5% of Patients with Inflammatory Bowel Disease and Colonic Strictures

Mathurin Fumery , Guillaume Pineton De Chambrun , Carmen Stefanescu , Anthony Buisson , Aude Bressenot et al.
Clinical Gastroenterology and Hepatology, 2015, 13 (10), pp.1770-1775. ⟨10.1016/j.cgh.2015.04.185⟩
Journal articles hal-01154234v1
Image document

Prevalence of anti-TNF contraindications in Crohn’s disease: A cross-sectional survey from the GETAID

Aurelien Amiot , Philippe Seksik , Jean-Marie Reimund , Maria Nachury , Romain Altwegg et al.
Digestive and Liver Disease, 2022, 54 (10), pp.1350-1357. ⟨10.1016/j.dld.2022.04.011⟩
Journal articles hal-03690498v1
Image document

Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study

Anne-Laure Mallet , Guillaume Bouguen , Guillaume Conroy , Xavier Roblin , Jean-Bernard Delobel et al.
Digestive and Liver Disease, 2017, 49 (3), pp.280-285. ⟨10.1016/j.dld.2016.12.001⟩
Journal articles hal-01483854v1

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients with Inflammatory Bowel Disease

Aurelien Amiot , Jean-Charles Grimaud , Laurent Peyrin-Biroulet , Jérome Filippi , Benjamin Pariente et al.
Clinical Gastroenterology and Hepatology, 2016, 14 (11), pp.1593-1601.e2. ⟨10.1016/j.cgh.2016.02.016⟩
Journal articles hal-01278611v1
Image document

Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study

Antoine Martin , Maria Nachury , Laurent Peyrin-Biroulet , Yoram Bouhnik , Stephane Nancey et al.
Journal of Crohn's & Colitis, 2020, 14 (7), pp.896-903. ⟨10.1093/ecco-jcc/jjaa005⟩
Journal articles hal-02442530v1
Image document

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti-Tumor Necrosis Factor Agents

Pauline Wils , Yoram Bouhnik , Pierre Michetti , Bernard Flourie , Hedia Brixi et al.
Clinical Gastroenterology and Hepatology, 2016, 14 (2), pp.242-250.e2. ⟨10.1016/j.cgh.2015.09.018⟩
Journal articles hal-01214012v1

Comparative Real-World Effectiveness of Vedolizumab and Ustekinumab for Patients with Ulcerative Colitis: A GETAID Multicentre Cohort Study

Antoine Meyer , Mathurin Fumery , Laurent Peyrin-Biroulet , Jérôme Filippi , Romain Altwegg et al.
Scandinavian Journal of Gastroenterology, 2022, 57 (12), pp.1454-1462. ⟨10.1080/00365521.2022.2095668⟩
Journal articles hal-03723440v1
Image document

The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease

Sara Tadbiri , Maria Nachury , Yoram Bouhnik , Mélanie Serrero , Xavier Hebuterne et al.
Journal of Crohn's and Colitis, 2021, 15 (5), pp.766-773. ⟨10.1093/ecco-jcc/jjaa244⟩
Journal articles hal-03038348v1

Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 Study.

Anthony Buisson , Mélanie Serrero , Laurie Orsat , Stéphane Nancey , Pauline Rivière et al.
Inflammatory Bowel Diseases, 2022, ⟨10.1093/ibd/izac119⟩
Journal articles hal-03723436v1